--- title: "Adjuvant Non-Small Cell Lung Cancer A081801 | Sutter Health" description: "Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO" url: "https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Adjuvant Non-Small Cell Lung Cancer A081801 # Adjuvant Non-Small Cell Lung Cancer A081801 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT04267848). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer. ![Edmund W Tai, M.D., FACP](https://dyn.mktgcdn.com/p/wYUVzA2p9c43sVmazBXuZrEqT_9gDAEd_juzF2bvph0/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Edmund W Tai, M.D., FACP Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/edmund-w-tai-md-facp-1049681048) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Adjuvant%20Non-Small%20Cell%20Lung%20Cancer%20A081801%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-stage-non-small-cell-lung-cancer-beamion-lung-3-2084403277) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer](https://www.sutterhealth.org/research/clinical-trials/adjuvant-monotherapy-vs-standard-of-care-early-stage-resectable-non-small-cell-lung-cancer-2082765455) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Coming Soon - Clinical trial ### [Adjuvant Non Small Lung Cancer TroFuse-019](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648) A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-c5851005-padl1nk-005-2064313501) PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) **Status:** Open to Enrollment - Clinical trial ### [Advanced Non-Small Cell Lung Cancer S1900K](https://www.sutterhealth.org/research/clinical-trials/interventional-lung-s1900k-lungmap-substudy-1049141939) A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Adjuvant Non-Small Cell Lung Cancer A081801"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#medicalwebpage","name":"Adjuvant Non-Small Cell Lung Cancer A081801","description":"Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#breadcrumblist"},"mentions":[{"@type":"Person","name":"Edmund W Tai, M.D., FACP","url":"https://www.sutterhealth.org/research/investigators/edmund-w-tai-md-facp-1049681048","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795#medicaltrial","name":"Adjuvant Non-Small Cell Lung Cancer A081801","alternateName":"Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO","url":"https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795","description":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.","identifier":"NCT04267848","code":{"@type":"MedicalCode","codeValue":"NCT04267848","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/ct2/show/NCT04267848","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Lung Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```